$IOVA
The potential money-printing machine is finally getting oiled and starting to hum.
Q2 revenue reached $99.3M, about 14% above management’s guidance and up 39% sequentially, MOST IMPORTANTLY, driven by approximately $91M of Amtagvi revenue rather than Proleukin stocking.
